OBJECTIVE: This study will examine if D-dimer and APTT testing can predict COVID-19 severity and aid triage and manage patients.
METHODS: 214 COVID-19 patients were enrolled and classified into two categories based on their respiratory manifestations; mild (126 cases) and severe (88 cases). Patient data regarding age, gender, D-Dimer level, and APTT level were collected. When both D-Dimer and APTT levels were abnormal, in this study, the patient was considered to have a coagulation disorder. Indicators of coagulation in the COVID-19 patients were collected and compared between the two groups. Chi-square (χ2) tests were used to determine the significant differences between coagulation disorders in the two groups.
RESULTS: Our findings showed that patients with coagulopathies were more likely to belong to the severe group. Within the two groups of patients, the rate of coagulation disorders was as follows: mild = 8.8 % within coagulation disorders, 4.8% within the two Groups; severe = 91.2 % within coagulation disorders, 77.8 % within the two Groups. There was a statistically significant relationship between coagulation disorder and severe COVID-19 patients compared to mild patients (p < 0.05).
CONCLUSIONS: Coagulation disorders are more likely to occur in severe COVID-19 patients. D-Dimer and APTT tests are significant indicators for predicting COVID-19 severity. Our research found an abnormal pattern of coagulation disorders and COVID-19 severity that should be considered in the COVID-19 treatment protocol.
目的:本研究将研究D-二聚体和APTT检测是否可以预测COVID-19的严重程度,并帮助患者分诊和管理。
方法:214例COVID-19患者根据其呼吸道表现分为轻度(126例)和重度(88例)两类。关于年龄的患者数据,性别,D-二聚体水平,收集APTT水平。当D-二聚体和APTT水平都异常时,在这项研究中,患者被认为患有凝血障碍.收集并比较两组患者的凝血指标。使用卡方(χ2)检验确定两组凝血障碍之间的显着差异。
结果:我们的研究结果表明,有凝血障碍的患者更可能属于重症组。在两组患者中,凝血障碍的发生率如下:轻度=凝血障碍中的8.8%,两组中有4.8%;严重=凝血障碍中的91.2%,两组中77.8%。与轻度患者相比,凝血障碍与重度COVID-19患者之间存在统计学上的显着关系(p<0.05)。
结论:重症COVID-19患者更容易发生凝血障碍。D-Dimer和APTT测试是预测COVID-19严重程度的重要指标。我们的研究发现凝血障碍和COVID-19严重程度的异常模式,应在COVID-19治疗方案中予以考虑。